Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian G Feagan

Showing results (271-280 of 464) with videos related to

Pageof 47
Sort By:
The American Journal of Gastroenterology|October 18, 2017
Systematic Review: Disease Activity Indices in Eosinophilic EsophagitisMarijn J Warners, Pieter Hindryckx, Barrett G Levesque, et al.
Journal of Crohn'S & Colitis|August 5, 2016
Evolving Concepts in Phases I and II Drug Development for Crohn's DiseaseVipul Jairath, Barrett G Levesque, Niels Vande Casteele, et al.
Gastroenterology|October 16, 2024
Placebo Rates in Crohn's Disease Randomized Clinical Trials: An Individual Patient Data Meta-AnalysisVirginia Solitano, Malcolm Hogan, Siddharth Singh, et al.
Journal of Crohn'S & Colitis|March 23, 2018
Corrigendum: Evolving Concepts in Phases I and II Drug Development for Crohn's DiseaseVipul Jairath, Barrett G Levesque, Niels Vande Casteele, et al.
Gastroenterology|February 8, 2018
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's DiseaseOmoniyi J Adedokun, Zhenhua Xu, Christopher Gasink, et al.
The New England Journal of Medicine|March 29, 2023
Vedolizumab for the Treatment of Chronic PouchitisSimon Travis, Mark S Silverberg, Silvio Danese, et al.
Inflammatory Bowel Diseases|September 2, 2016
Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel DiseasesSubrata Ghosh, William J Sandborn, Jean-Frederic Colombel, et al.
The New England Journal of Medicine|May 5, 2016
Ozanimod Induction and Maintenance Treatment for Ulcerative ColitisWilliam J Sandborn, Brian G Feagan, Douglas C Wolf, et al.
Inflammatory Bowel Diseases|April 15, 2017
Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's DiseaseWilliam J Sandborn, Douglas C Wolf, Gordana Kosutic, et al.
Gastro Hep Advances|January 13, 2025
Early Endoscopic Outcomes After Risankizumab Are Associated With Fewer Hospitalizations and Surgeries in Crohn's DiseaseBrian G Feagan, Jean-Frederic Colombel, Remo Panaccione, et al.
Pageof 47

Showing results (271-280 of 464) with videos related to

Sort By:
Pageof 47
The American Journal of Gastroenterology|October 18, 2017
Systematic Review: Disease Activity Indices in Eosinophilic EsophagitisMarijn J Warners, Pieter Hindryckx, Barrett G Levesque, et al.
Journal of Crohn'S & Colitis|August 5, 2016
Evolving Concepts in Phases I and II Drug Development for Crohn's DiseaseVipul Jairath, Barrett G Levesque, Niels Vande Casteele, et al.
Gastroenterology|October 16, 2024
Placebo Rates in Crohn's Disease Randomized Clinical Trials: An Individual Patient Data Meta-AnalysisVirginia Solitano, Malcolm Hogan, Siddharth Singh, et al.
Journal of Crohn'S & Colitis|March 23, 2018
Corrigendum: Evolving Concepts in Phases I and II Drug Development for Crohn's DiseaseVipul Jairath, Barrett G Levesque, Niels Vande Casteele, et al.
Gastroenterology|February 8, 2018
Pharmacokinetics and Exposure Response Relationships of Ustekinumab in Patients With Crohn's DiseaseOmoniyi J Adedokun, Zhenhua Xu, Christopher Gasink, et al.
The New England Journal of Medicine|March 29, 2023
Vedolizumab for the Treatment of Chronic PouchitisSimon Travis, Mark S Silverberg, Silvio Danese, et al.
Inflammatory Bowel Diseases|September 2, 2016
Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel DiseasesSubrata Ghosh, William J Sandborn, Jean-Frederic Colombel, et al.
The New England Journal of Medicine|May 5, 2016
Ozanimod Induction and Maintenance Treatment for Ulcerative ColitisWilliam J Sandborn, Brian G Feagan, Douglas C Wolf, et al.
Inflammatory Bowel Diseases|April 15, 2017
Effects of Transient and Persistent Anti-drug Antibodies to Certolizumab Pegol: Longitudinal Data from a 7-Year Study in Crohn's DiseaseWilliam J Sandborn, Douglas C Wolf, Gordana Kosutic, et al.
Gastro Hep Advances|January 13, 2025
Early Endoscopic Outcomes After Risankizumab Are Associated With Fewer Hospitalizations and Surgeries in Crohn's DiseaseBrian G Feagan, Jean-Frederic Colombel, Remo Panaccione, et al.
Pageof 47